



Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects

Jeremy M. Simon, Kathryn E. Hacker, Darshan Singh, et al.

Genome Res. 2014 24: 241-250 originally published online October 24, 2013
Access the most recent version at doi:[10.1101/gr.158253.113](https://doi.org/10.1101/gr.158253.113)

References This article cites 58 articles, 19 of which can be accessed free at:
<http://genome.cshlp.org/content/24/2/241.full.html#ref-list-1>

Creative Commons License This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genome.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), as described at <http://creativecommons.org/licenses/by-nc/3.0/>.

Email Alerting Service Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

An advertisement banner with a teal background. On the left, the text reads 'CRISPR and RNAi Genetic Screening. Your new superpower.' In the center, there is a white-bordered box containing the words 'LEARN MORE'. On the right, there is a photograph of a woman wearing a red and white superhero cape and mask, and the Cellecta logo, which consists of a cluster of green dots.

To subscribe to *Genome Research* go to:
<https://genome.cshlp.org/subscriptions>

Research

Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects

Jeremy M. Simon,^{1,2,3,14} Kathryn E. Hacker,^{1,3,14} Darshan Singh,^{2,4}
 A. Rose Brannon,^{1,3,11} Joel S. Parker,^{1,3} Matthew Weiser,^{1,2} Thai H. Ho,^{5,12}
 Pei-Fen Kuan,^{3,6} Eric Jonasch,⁵ Terrence S. Furey,^{1,3,7,8} Jan F. Prins,⁴
 Jason D. Lieb,^{1,3,7,8,13,15} W. Kimryn Rathmell,^{1,3,9,15} and Ian J. Davis^{1,3,7,10,15,16}

¹Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27514, USA; ²Curriculum in Bioinformatics and Computational Biology, University of North Carolina, Chapel Hill, North Carolina 27514, USA; ³Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27514, USA; ⁴Department of Computer Science, University of North Carolina, Chapel Hill, North Carolina 27514, USA; ⁵Department of Medical Oncology, MD Anderson Cancer Center, Houston, Texas 77030, USA; ⁶Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina 27514, USA; ⁷Carolina Center for Genome Sciences, University of North Carolina, Chapel Hill, North Carolina 27514, USA; ⁸Department of Biology, University of North Carolina, Chapel Hill, North Carolina 27514, USA; ⁹Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27514, USA; ¹⁰Department of Pediatrics, University of North Carolina, Chapel Hill, North Carolina 27514, USA

Comprehensive sequencing of human cancers has identified recurrent mutations in genes encoding chromatin regulatory proteins. For clear cell renal cell carcinoma (ccRCC), three of the five commonly mutated genes encode the chromatin regulators PBRM1, SETD2, and BAP1. How these mutations alter the chromatin landscape and transcriptional program in ccRCC or other cancers is not understood. Here, we identified alterations in chromatin organization and transcript profiles associated with mutations in chromatin regulators in a large cohort of primary human kidney tumors. By associating variation in chromatin organization with mutations in *SETD2*, which encodes the enzyme responsible for H3K36 trimethylation, we found that changes in chromatin accessibility occurred primarily within actively transcribed genes. This increase in chromatin accessibility was linked with widespread alterations in RNA processing, including intron retention and aberrant splicing, affecting ~25% of all expressed genes. Furthermore, decreased nucleosome occupancy proximal to misspliced exons was observed in tumors lacking H3K36me3. These results directly link mutations in *SETD2* to chromatin accessibility changes and RNA processing defects in cancer. Detecting the functional consequences of specific mutations in chromatin regulatory proteins in primary human samples could ultimately inform the therapeutic application of an emerging class of chromatin-targeted compounds.

[Supplemental material is available for this article.]

Large-scale cancer sequencing studies continue to identify mutations in genes encoding chromatin regulatory proteins in a wide variety of human cancers. The downstream molecular consequences of these mutations, however, remain unknown. Clear cell renal cell carcinoma (ccRCC) is a particularly relevant model for the study of chromatin regulation in cancer for several reasons. First, relative to mutations in other classes of genes, ccRCCs are marked by frequent mutation of chromatin regulators (Dagliesh et al. 2010; Varela et al. 2011; Pena-Llopis et al. 2012; Ryan and Bernstein 2012). Three of the more commonly mutated genes in

ccRCC include chromatin modifiers *SETD2*, *PBRM1*, and *BAP1* (Dagliesh et al. 2010; Varela et al. 2011; Pena-Llopis et al. 2012; Kapur et al. 2013), suggesting that alterations at the level of chromatin may play a prominent role in the development of ccRCC (Dagliesh et al. 2010; Varela et al. 2011). Mutation-associated changes in chromatin organization may promote oncogenesis in novel ways, and it has been suggested that specific chromatin regulator mutations may confer differences in patient survival or associate with more advanced disease (Hakimi et al. 2012). However, the downstream effect of these mutations on tumor chromatin biology remains unknown. Second, this cancer is tightly associated with a distinct transcriptional program resulting from the inactivation of the von Hippel–Lindau (*VHL*) tumor suppressor gene (Kim and Kaelin 2004; Bratslavsky et al. 2007; Nickerson et al. 2008; Jonasch et al. 2012). The loss of *VHL* results in the stabiliza-

Present addresses: ¹¹Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; ¹²Division of Hematology/Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ 85054, USA; ¹³Department of Molecular Biology and Lewis-Sigler Institute for Integrative Genomics, Princeton University, 144 Carl Icahn Laboratory, Princeton, NJ 08544, USA.

¹⁴These authors contributed equally to this work.

¹⁵These authors contributed equally to this work.

¹⁶Corresponding author

E-mail ijdavis@email.unc.edu

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.158253.113>.

© 2014 Simon et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first six months after the full-issue publication date (see <http://genome.cshlp.org/site/misc/terms.xhtml>). After six months, it is available under a Creative Commons License (Attribution-NonCommercial 3.0 Unported), as described at <http://creativecommons.org/licenses/by-nc/3.0/>.

tion of hypoxia inducible factors (HIFs), transcription factors that activate a complex program of downstream targets, including vascular endothelial growth factor (VEGF) and other genes (Gordan et al. 2008; Gore and Larkin 2011; Jonasch et al. 2012). Third, besides *VHL* and chromatin regulators, mutations in other cancer-associated pathways are generally absent from ccRCC tumors.

Elucidating the functional consequences of mutations in genes encoding chromatin regulatory proteins on chromatin organization and transcription in human tumor specimens requires the application of techniques developed for cultured cells to primary human tissues. Formaldehyde-assisted isolation of regulatory elements (FAIRE) interrogates chromatin accessibility by isolating nucleosome-depleted regions of DNA (Nagy et al. 2003; Hogan et al. 2006; Giresi et al. 2007; Giresi and Lieb 2009; Simon et al. 2012). These regions harbor regulatory elements such as active transcriptional start sites, transcriptional enhancers, insulators, silencers, and locus control regions (Hogan et al. 2006; Giresi et al. 2007; Giresi and Lieb 2009; Gaulton et al. 2010; Song et al. 2011; Simon et al. 2012). As a component of the ENCODE Project, FAIRE has been used to identify regulatory elements across a wide range of cell lines (Song et al. 2011; Thurman et al. 2012). However, the application of FAIRE to primary human tissue or to explore the association between chromatin and genetic alterations in cancer has yet to be evaluated.

We modified FAIRE for use on primary human clinical samples to define the chromatin landscape in a large cohort of ccRCC tumors and matched normal tissues. We identified tumor- and normal-kidney-specific classes of chromatin accessibility changes, as well as those associated with chromatin modifier mutations. We focused our study on *SETD2*, which trimethylates lysine-36 on histone H3 (H3K36me3) (Rayasam et al. 2003; Sun et al. 2005; Brown et al. 2006; Edmunds et al. 2008; Yoh et al. 2008; Duns et al. 2010). Associated with the RNA polymerase II complex, *SETD2*-dependent methylation tends to occur toward the 3' ends of genes and over nucleosomes located at exons (Edmunds et al. 2008; Kolasinska-Zwiercz et al. 2009; Schwartz et al. 2009). *SETD2* and H3K36me3 seem to play a role in cotranscriptional RNA processing. In cell-culture-based studies, silencing of *SETD2* or readers of H3K36me3 has been associated with differential exon inclusion for individual genes (Luco et al. 2010; Pradeepa et al. 2012) and alternative transcription start site utilization (Carvalho et al. 2013). However, the consequence of *SETD2* deficiency on chromatin organization and RNA processing remains to be explored on a genome-wide scale and in a disease-relevant model. *SETD2* is mutated in ~12% of primary human ccRCC tumors and results in H3K36me3 deficiency (Gerlinger et al. 2012). A similar rate of *SETD2* mutation has also been observed in high-grade gliomas (Fontebasso et al. 2013). A recent study of intratumor heterogeneity in ccRCC identified distinct *SETD2* mutations in all subsections of the same tumor suggesting the importance of disrupting *SETD2* function for a subset of tumors (Gerlinger et al. 2012).

We found that *SETD2* mutation was associated with chromatin accessibility differences preferentially in gene bodies, and these genes frequently exhibited RNA processing defects. Nearly 25% of all expressed genes demonstrated aberrancies in splicing, including exon skipping, intron retention, and alternative transcription start and termination sites. We observed that misspliced exons were marked by a striking increase in chromatin accessibility immediately upstream of the aberrant splice and a loss of nucleosome occupancy directly over the exon. This study represents the first investigation of chromatin organization in human tumors to identify the impact of chromatin modifier mutations on the

genomic landscape. Understanding chromatin dysregulation in cancer may ultimately inform the application of emerging classes of chromatin-targeted small molecules in renal cancer.

Results

Differences in chromatin accessibility between tumors and normal kidney tissue corroborate the underlying role of HIF in ccRCC

We performed FAIRE-seq on 42 primary ccRCC tumor samples as well as uninvolved matched normal kidney from seven of these patients (Supplemental Fig. S1A,B). We identified about 11,000 500-bp genomic intervals with differences in chromatin accessibility that discriminated tumors from normal kidney (two-sided *t*-test, $P < 0.01$) (Fig. 1A,B). For ~70% of these regions, FAIRE signal was increased in the tumor samples, indicative of nucleosome depletion. Using hierarchical clustering, three clusters of genomic loci emerged: Two were marked by tumor-specific nucleosome depletion (Clusters 1 and 2), and another was characterized by nucleosome depletion in normal kidney tissue but not in tumors (Cluster 3). Virtually all tumors exhibited nucleosome depletion at the sites in Cluster 1, whereas ~50% of tumors demonstrated FAIRE enrichment at regions in Cluster 2.

We then examined each cluster for shared biological associations among the loci and adjacent genes. Regions in each cluster were associated with genes (GREAT) (McLean et al. 2010). For sites in Cluster 1, 2274 genes were identified, many of which were members of several cancer-associated gene sets. Particularly interesting in the setting of ccRCC, where HIF transcription factor family stabilization and activation of hypoxia response genes is a central feature of this tumor type, we found that the most significantly associated genes in this cluster were involved in HIF activation and hypoxia regulation (Fig. 1C; full list of associations for each cluster in Supplemental Fig. S2). This association was not observed for regions in Cluster 2 or 3 (Supplemental Fig. S2). Analysis of the sequences in Cluster 1 identified several highly enriched transcription factor (TF) motifs (Heinz et al. 2010), including the hypoxia response element consensus binding sequence (Fig. 1D). We additionally found that previously identified HIF1A and HIF2A (EPAS1) binding sites (Schodel et al. 2011) only significantly overlapped loci in Cluster 1 ($P < 0.001$) (Fig. 1B,E). The detection of features associated with the hypoxia response through variation in chromatin accessibility is consistent with the unique link between HIF activity and ccRCC, and these results demonstrate the ability of FAIRE to detect central biological pathways through the identification variations in chromatin organization in an unbiased fashion.

SETD2 mutations link H3K36me3 loss with changes in chromatin accessibility

To identify mutations in chromatin modifiers within tumor samples, we genotyped 33 unique ccRCC tumors (from our cohort of 42 above) and the same seven matched normal kidney specimens (Supplemental Fig. S1A,B). We classified sequence variants based on predicted ability to confer severe protein structural changes, including frameshift, nonsense, and mutations altering an annotated splice site ("high severity"), as well as missense mutations ("moderate severity") (Fig. 2A). Approximately half of the *SETD2* mutations in these classes were predicted to disrupt the catalytic SET domain. High- and moderate-severity mutations were also observed in other domains in *SETD2* including the SRI domain,




Figure 1. Regions of tumor-specific nucleosome eviction identify the underlying role of HIF in ccRCC. (A) Hierarchical clustering of median-centered FAIRE signal in windows with significant differences between tumors and normal kidney (two-sided t -test, $P < 0.01$). (B) FAIRE-seq tracks for ccRCC (black) and uninvolved kidney (red) at two loci. (Blue) ChIP-seq signals (Schodel et al. 2011) from HIF1A, HIF2A, and ARNT. (C) The top five Gene Ontology associations ($q < 1 \times 10^{-5}$) with sites in Cluster 1 are shown. (D) Transcription factor binding motifs enriched in Cluster 1 compared with local background 500-bp flanking windows (>2.5 -fold over background and present in at least 10% of the Cluster 1 windows). P -values relative to local background are shown. (E) Fraction of HIF1A and HIF2A binding sites (Schodel et al. 2011) that overlap the loci in Clusters 1, 2, and 3 compared with permuted controls. Errors bars represent standard deviation (SD).

which mediates the interaction with RNA polymerase II. A prediction of copy number using the genotyping data also revealed that with the exception of one tumor (which displayed one high- and one moderate-severity mutation) loss of heterozygosity coincided with mutations in *SETD2* (Supplemental Fig. S4C).

We identified about 7000 500-bp windows exhibiting significant variation in FAIRE enrichment between *SETD2*-mutant and

SETD2-normal tumors (two-sided t -test, $P < 0.01$) (Fig. 2B; Supplemental Fig. S1C). In the *SETD2*-mutant tumors, FAIRE signal at these regions was most commonly increased (80%), suggesting that *SETD2* loss is preferentially associated with greater chromatin accessibility. *SETD2* trimethylates H3K36 typically at gene bodies (Barski et al. 2007; Kolasinska-Zwiercz et al. 2009). Regions with increased FAIRE signal in *SETD2*-mutated tumors (one-sided t -test,




Figure 2. *SETD2* mutations link H3K36me3 loss with changes in chromatin accessibility. (A) Schematic representation of *SETD2* mutations predicted to have high or moderate severity on protein structure. (B) Hierarchical clustering of median-centered FAIRE signal in windows with significant differences between *SETD2* mutant tumors (red) and tumors without *SETD2* mutation (gray) (2-sided *t*-test, $P < 0.01$). (White) Samples not genotyped. (C) Proportions of nucleosome-depleted loci overlapping H3K36me3-marked regions compared with loci with permuted genomic coordinates. Error bars represent SD. (D) Representative immunostaining of two ccRCC tumor-normal pairs on the tissue microarray. (E) Quantification of H3-normalized H3K36me3 intensity across 11 normal kidney and 69 renal tumors. Mutation severity (high, red; moderate, green; none, blue) is indicated. (White) Samples with unknown *SETD2* mutation status. The threshold for H3K36me3 deficiency was set to the lowest observed intensity in normal tissue (dashed line).

$P < 0.01$) also overlapped gene bodies (49% of sites), most of which (91%) were marked by H3K36me3 in normal kidney ($P < 0.001$ relative to permuted control). More specifically, regions of increased chromatin accessibility associated with *SETD2* mutation were enriched directly over the same domains marked by H3K36me3 (24.5%, $P < 0.001$ relative to permuted control) (Fig. 2C). In contrast, the regions with decreased FAIRE signal showed no association with H3K36me3 and, in fact, showed a significant underrepresentation relative to permuted control ($P < 0.001$). As an additional control, we tested for this association at regions with in-

creased FAIRE signal in *PBRM1*-mutant tumors, which we expected to yield a divergent set of loci. Indeed, areas of increased chromatin accessibility associated with this mutation were significantly underrepresented at H3K36me3-marked regions ($P < 0.001$ relative to permuted control). Together, these data indicate that regions of nucleosome depletion associated with *SETD2* mutation preferentially occur at genic sites normally marked by H3K36me3.

Although *SETD2* is responsible for trimethylation of H3K36, other mechanisms may influence H3K36 methylation status. Moreover, the effects of specific classes of *SETD2* mutations in human tumors on H3K36 methylation are not known. We quantified H3K36me3 on a tissue microarray (69 tumors, 11 matched normal kidneys) (Fig. 2D; Supplemental Fig. S1B). Whereas normal kidney samples demonstrated consistent nuclear H3K36me3 signal (Fig. 2E), tumors displayed a range of staining intensity, with 53% of tumors exhibiting reduced H3K36me3 intensity. Hereafter, this group of tumors is referred to as “H3K36me3 deficient.” Each of the eight tumors that contained mutations predicted to affect *SETD2* activity and screened by IHC demonstrated H3K36me3 deficiency (Fig. 2E). Tumors containing mutations before the SET domain (Q320fs, E978*, and Q1409*) displayed a complete loss of H3K36me3 signal. However, tumors with *SETD2* mutations located within the SET domain (G1681fs) or in the SRI domain (R2510L) displayed reduced H3K36me3 signal, suggesting that some mutations may cause a partial loss of function. Several tumors (eight of 13) without identified *SETD2* mutations also exhibited reduced H3K36me3 signal. *SETD2* was undetectable by immunohistochemistry in two of these tumors, whereas others exhibited decreased *SETD2* mRNA, suggesting alternate mechanisms for H3K36me3 loss (Supplemental Fig. S4). We also observed evidence for *SETD2* gene hemizyosity in other H3K36me3-deficient *SETD2*-normal tumors, suggest-

ing that loss of heterozygosity may contribute to deficiency in H3K36 methylating activity (Supplemental Fig. S4C). Interestingly, one tumor (Tumor 25 in Supplemental Fig. S4C) did not exhibit a copy number loss, carried two *SETD2* mutations (E1846*, high severity; I2499S, moderate severity), and showed a moderate H3K36me3 deficiency (an intensity value of 0.36 in Fig. 2E). We would thus predict that at least one of these mutations is hypomorphic, thus explaining the intermediate magnitude of the H3K36me3 deficiency. Similarly, we detected two mutations in *SETD2* in another tumor (Tumor 3 in Supplemental Fig. S4C),

which exhibited a global loss in H3K36me3 staining along with copy number loss. These data suggest that either the tumor cell population was heterogeneous and the remaining allele was differentially mutated in each population (as was observed in Gerlinger et al. 2012) or that the one remaining allele was mutated in two locations. Together, these data illustrate that defective H3K36me3 is a common feature of ccRCC and that the *SETD2* genotype alone underestimates H3K36me3 deficiency.

SETD2 mutation is associated with DNA hypomethylation proximal to sites of nucleosome depletion

In many higher eukaryotes, the H3K36me3 mark is recognized by several chromatin readers, one of which is the PWWP domain of the DNA methyltransferase DNMT3A, resulting in DNA methylation proximal to the marked histone (Dhayalan et al. 2010). Using ccRCC DNA methylation data from The Cancer Genome Atlas (TCGA), we observed localized changes ($P < 0.05$) in DNA methylation, primarily (>70% of probes) DNA hypomethylation, in *SETD2*-mutant tumors of the TCGA data set at nucleosome-depleted regions identified in our *SETD2*-mutant tumors (Supplemental Fig. S5). These data link changes in DNA methylation to sites of nucleosome eviction and/or loss of H3K36me3 through *SETD2* mutation. This result underscores the importance of H3K36me3 and how its loss may confer a multifaceted alteration in the epigenome.

Intron retention and splicing defects affect a large fraction of genes with altered chromatin accessibility in *SETD2* mutant tumors

H3K36me3 has been previously implicated in RNA processing (Luco et al. 2010; de Almeida et al. 2011; Pradeepa et al. 2012), an association not previously examined in primary tissues or in a disease-relevant model. We thus hypothesized that H3K36me3 deficiency would alter RNA processing and splicing in tumors specifically at genes with altered chromatin accessibility. To assess total RNA, including pre-mRNA and nonpolyadenylated transcripts, we performed RNA-seq on ribosome-depleted RNA from 33 tumors, all but one of which was annotated with mutational status (Fig. 2; Supplemental Fig. S1); six tumors without H3K36me3 status assessed by immunohistochemistry were omitted. We observed that H3K36me3-deficient tumors displayed a striking enrichment of intronic pre-mRNA signal compared with tumors with normal H3K36me3 levels. To quantify this effect, we calculated intron retention scores (IRS), which reflect the ratio of intronic to exonic RNA-seq reads on a gene-by-gene basis for each tumor. IRS values range

from 0 to 1, where a score of 0 represents a completely spliced message and a score of 1 represents uniform genic coverage. Intron retention was dramatically increased in the H3K36me3-deficient tumors at 95% of the transcripts (6551 in total) marked by H3K36me3 in normal kidney and by nucleosome depletion (one-sided *t*-test, $P < 0.01$) in H3K36me3-deficient tumors (Fig. 3A,C; Supplemental Figs. S1B, S6A, S7). To confirm this result, we performed ChIP-seq from an independent normal kidney sample (Supplemental Fig. S6B). Of the 6551 transcripts initially identified (Fig. 3A; Supplemental Fig. S1), 6101 were identified using the second normal kidney sample, representing a 93% overlap. When the 6551 transcripts were instead stratified by *PBRM1* mutation status, widespread intron retention was not observed (Fig. 3B), suggesting that this effect is specific to tumors with H3K36me3 deficiency. Many of the affected genes are part of recognized cancer-associated pathways, including known tumor suppressors (e.g., *MET*, *PTEN*, and *TP53*), genes in the DNA repair pathway (e.g., *ATR*, *RAD50*, *POLN*, and *XRCC1*), and cell cycle regulators (e.g., *CCNB1*




Figure 3. H3K36me3 deficiency is associated with intron retention. Intron retention scores for selected genes (Supplemental Fig. S1C) were compared between (A) H3K36me3-deficient tumors and H3K36me3-normal tumors, and (B) *PBRM1*-mutant and *PBRM1*-normal tumors. (C) Example genes exhibiting increased intron retention in H3K36me3-deficient tumors (top, *PPP2CB*; bottom, *COX6C*). Intron retention scores, genic coverage (calculated with both intron and exon reads), and exonic coverage (calculated only with exonic reads) are provided for two H3K36me3-deficient tumors (red) and two H3K36me3-normal tumors (black).

and *CCND3*), as well as numerous receptors and protein kinases (e.g., *BRAF*, *EGFR*, *PIK3CA*, and *TGFBR3*) (Supplemental Fig. S8).

Widespread RNA processing defects linked with *SETD2* mutations persist in the mature RNA pool and are marked by altered chromatin accessibility

To test whether observed changes in the pre-mRNA messages persist into mature polyadenylated RNA, we analyzed TCGA RNA-

seq data derived from poly(A)⁺ mRNA isolated from a large cohort ($n = 416$) of ccRCC tumors. Applying a gene-model-independent algorithm for read mapping and transcript prediction (Singh et al. 2011), we observed that *SETD2*-mutant tumors exhibited significant alterations in transcript processing (3929 transcripts) (Fig. 4A,B). Alterations included intron retention (12% of altered transcripts) (Supplemental Figs. S1B, S9), variation in exon utilization (66% of altered transcripts) (Fig. 4B,C; Supplemental S10), and differences in transcriptional start and termination site usage (22%




Figure 4. Widespread RNA processing defects linked with *SETD2* mutations persist in the mature RNA pool and are marked by altered chromatin accessibility. (A) Splicing differences (see Methods) between *SETD2*-mutant and *SETD2*-normal tumors (red) compared with a permuted control (blue) are plotted as a cumulative distribution function. (B) Significance of the difference in ratios between *SETD2*-mutant and *SETD2*-normal tumors (x -axis) plotted against the scrambled control (y -axis). Points are colored by the class of RNA processing aberrancy. (Gray box) Significance ($P = 0.01$) in the *SETD2*-mutant-normal comparison, but not significant in the control comparison. The percentages of significant differences in transcript processing are also presented. (C) Schematic of *AP2A1* splicing. Exon skipping was represented as the ratio of included exon coverage to the sum of the exon and the spliced form. The skipped exon ratio is provided for *SETD2*-mutant tumors (red) and *SETD2*-normal tumors (black). (D) Quantitative PCR across two *USH1C* alternative exon utilization sites identified by RNA-seq for three *SETD2*-normal tumors (black) and two *SETD2*-mutant tumors (red). Error bars represent standard error. (E) FAIRE signal plotted around the exon start (± 3 kb) of misspliced exons (left), random internal exon starts (middle), and random genic positions (right) for H3K36me3-deficient tumors (red) and H3K36me3-normal tumors (black). (Gray) H3K36me3 ChIP-seq signal from normal kidney tissue.

of altered transcripts). We also observed the generation of previously unannotated splice isoforms, which we validated by quantitative PCR in independent tumor samples (Fig. 4D). Aberrancies in RNA processing were detected more frequently in highly expressed genes (Supplemental Fig. S11A). Low-abundance messages may preclude the detection of differences in transcript processing. However, overall expression of genes exhibiting defects in RNA processing was comparable between *SETD2*-mutant and *SETD2*-normal tumors (Supplemental Fig. S11B).

Since H3K36me3 preferentially marks well-positioned exonic nucleosomes (Edmunds et al. 2008; Kolasinska-Zwierz et al. 2009; Schwartz et al. 2009), we analyzed chromatin accessibility around the intron–exon boundary of misspliced exons. H3K36me3-normal tumors demonstrated an expected reduction of FAIRE signal immediately downstream from intron/exon junctions as well as a concomitant enrichment in H3K36me3 (from ChIP-seq in normal kidney), indicative of a well-positioned exonic nucleosome (Fig. 4E, left), corroborating previous reports (Kolasinska-Zwierz et al. 2009). Strikingly, in H3K36me3-deficient tumors, evidence of the exonic nucleosome was lost, and a dramatic increase in chromatin accessibility was observed immediately upstream (50 bp) of the intron/exon junction (Fig. 4E, left, red line). This pattern was also evident, although less pronounced, at internal exon start sites of random genes (Fig. 4E, middle) but completely absent at random genic positions (Fig. 4E, right). Changes in chromatin accessibility even at internal exons chosen regardless of whether they exhibited a splicing defect may indicate a more widespread defect that may not always result in detectable variation in splicing. These data demonstrate the ability to detect subtle variations in chromatin organization in primary human tumors and link H3K36me3 loss with alterations in chromatin accessibility at exons.

Discussion

To identify the genomic consequences of mutated chromatin regulators, we modified and applied FAIRE-seq to a large cohort of primary kidney tumors. Using an unbiased approach, we identified variation in chromatin accessibility distinguishing tumors from normal kidney. Tumor-specific open chromatin corresponded to HIF-targeted sites and was linked to genes involved in the hypoxia response. This result reflects the well-studied association of ccRCC development with *VHL* inactivation and HIF stabilization. These data also serve to validate the use of FAIRE in primary tumors to detect biologically meaningful pathways.

We then associated variation in chromatin accessibility with mutations in chromatin regulators. Focusing on *SETD2*, we observed widespread increases in chromatin accessibility, especially in gene bodies typically harboring H3K36me3 in normal kidney tissue. A recent report suggested that *SETD2* silencing in cultured cells results in alternative internal transcriptional start sites (Carvalho et al. 2013), akin to cryptic initiation observed in yeast (Carrozza et al. 2005; Lickwar et al. 2009). Our data using human tumor specimens support a more diverse model for transcriptional defects, including retention of introns, missplicing of exons, and usage of alternative transcriptional start or end sites. These defects were widespread, affecting nearly 25% of all expressed genes, and defects were more common in highly transcribed genes.

Moreover, we found a surprising increase in chromatin accessibility immediately upstream (50 bp) of misspliced exons in *SETD2*-mutated tumors. This result suggests a mechanism by which the altered inclusion of the downstream exon is related to nucleosome positioning over the exon itself as well as the adjacent up-

stream nucleosome. Nucleosome positioning and histone modifications (including H3K36me3) are known to regulate multiple processes involved with splicing, including changes in the speed or pausing of RNA polymerase (Kadener et al. 2001; Howe et al. 2003; Batsche et al. 2006; Kornblihtt 2007; Munoz et al. 2009), and the ability for splicing machinery to appropriately recognize the splice donor and acceptor. Our finding also suggests that the positioning of this upstream nucleosome may be related to trimethylation of H3K36 on the exonic nucleosome. In *Saccharomyces cerevisiae*, loss of Set2 leads to destabilization of nucleosomes through hyperacetylation of gene bodies and cryptic transcriptional initiation (Carrozza et al. 2005; Lickwar et al. 2009). Since hyperacetylation was not observed following *SETD2* silencing (Edmunds et al. 2008), the increased chromatin accessibility we observed over gene bodies may therefore represent nucleosome destabilization in a hyperacetylation-independent manner. Although our results directly link *SETD2* mutation and H3K36 trimethylation to chromatin accessibility, studies that specifically examine nucleosome positioning and histone modification will be necessary to fully investigate this potential mechanism.

Although our data associate *SETD2* mutations/H3K36me3 deficiency with aberrant RNA processing, exactly how this dysregulation contributes to tumorigenesis remains unknown. A significant fraction of the deregulated transcripts include known tumor suppressors, DNA damage response proteins, and kinases. Strikingly, 58% of genes with altered splicing patterns (Fig. 4A,B) encode annotated phosphoproteins ($P = 7.3 \times 10^{-109}$), representing an enrichment exceeding that of genes annotated as having alternate splice isoforms ($P = 2 \times 10^{-60}$), a finding also observed in genes exhibiting retained introns (Supplemental Figs. S8, S12). Alterations in the abundance, stability, or splicing of RNA could induce changes in the phosphoproteome and disrupt normal cellular signaling and growth checkpoints, leading to tumorigenesis. Deregulated signaling as well as transcriptional defects provide numerous putative targets for therapeutic exploitation. Additionally, the application of FAIRE, or IHC for H3K36 trimethylation, could enable the classification of clinical specimens into functional tumor subtypes.

This study advances our understanding of the relationship between genetic alterations affecting chromatin organization and alterations in transcription. RNA processing defects in a large fraction of expressed genes, many of which are tumor suppressors critical for cellular function, may be a common phenotype of many cancers. Comprehensive mapping of the chromatin landscape in primary tumors offers a new tool for understanding the functional consequences of chromatin modifier mutations in human disease.

Methods

Formaldehyde-assisted isolation of regulatory elements (FAIRE) and hierarchical clustering of differentially open chromatin

FAIRE was performed as previously described (Simon et al. 2012). Sequencing was performed using 36- or 50-bp single-end reads (Illumina GA IIx or HiSeq 2000). Reads were filtered using TagDust (Lassmann et al. 2009) and aligned to the reference human genome (hg19) with Bowtie (Li and Durbin 2009) using default parameters. Reads were counted in 500-bp sliding windows across the genome, normalized for sequencing depth, and adjusted for batch effects using Principal Components Analysis (PCA). One outlier

normal kidney sample was removed at this step, and all normal kidney samples were removed for subsequent tumor-only analyses. For clustering analyses, only windows with sufficient sequencing depth (row average > 0.25) were retained; groups were compared using one- or two-sided *t*-tests ($P < 0.01$), clustered and plotted (Saldanha 2004). Feature intersections were computed using BEDTools (Quinlan and Hall 2010).

Reprocessing of HIF1A, HIF2A, and ARNT ChIP-seq data

ChIP-seq reads for HIF1A, HIF2A, and ARNT (Schodel et al. 2011) were filtered using TagDust (Lassmann et al. 2009) and aligned to the reference human genome (hg19) using Bowtie (Li and Durbin 2009) requiring unique read placement. Binding sites for HIF1A and HIF2A were identified using MACS (Feng et al. 2012), with a shift-size of 250 bp and significant to $q < 0.05$.

Ontologies associated with differentially open chromatin

Regions from Clusters 1–3 were associated with Gene Ontologies using GREAT (McLean et al. 2010) using all possible 500-bp windows as background. The top five ontologies with $q < 1 \times 10^{-5}$ were presented; full Gene Ontology associations are supplied in Supplemental Figure S3.

Motif analysis

Significantly overenriched known transcription factor (TF) motifs were identified using HOMER (Heinz et al. 2010). The 500-bp flanking region was used as local background. Only those TF motifs whose enrichment over background exceeded 2.5-fold were present in at least 10% of the target sequence, and $q < 0.0001$ were presented in Figure 1D. Highly similar entries were merged.

SureSelect custom capture and mutation calling

Genotyping was performed using the SureSelect XT Custom Capture (Agilent). Multiplexing was achieved using TruSeq adapters (Illumina); samples were pooled prior to the capture and amplified post-capture using TruSeq PCR primers (Illumina). Blocking reagents were replaced with water to avoid cross-reactivity. Sequencing was performed using 50-bp paired-end reads (Illumina HiSeq 2000). Reads were aligned to the reference human genome (hg19) using BWA (Li and Durbin 2009). Genes were sequenced to an average coverage of 200× with 85% of the target sequenced to at least 50×. Genotypes were determined using the Genome Analysis Toolkit (GATK) (McKenna et al. 2010) “Better” protocol. Only high-confidence (quality score >100) variants predicted to have high or moderate severity and not reported in dbSNP (v129) were considered.

Histone methylation ChIP-seq and data processing

ChIP for H3K36me3 and input DNA from normal kidney was sequenced on the Illumina Genome Analyzer II. Reads were aligned to the reference genome (hg19) using Bowtie requiring unique alignment. H3K36me3 sites were called first using ZINBA (Rashid et al. 2011), then merged to call broader domains by merging nearby sites using Galaxy (Goecks et al. 2010); two or more sites within 5 kb were merged. The average H3K36me3 signal across gene bodies was plotted using CEAS (Shin et al. 2009).

Feature overlap permutations

Significance of overlap between sites of differentially open chromatin associated with *SETD2* or *PBRM1* mutations and H3K36me3 sites was determined by permutation. First, the overlap between

the actual set of significant windows and histone methylation was computed. Then the same number of randomly selected windows from the full list (regardless of significance) was selected 1000 times, and an empirical *P*-value was determined by counting the number of times the overlap of the permuted set exceeded that of the actual set.

Tissue microarray construction and immunohistochemistry

Tissue microarrays (TMAs) were constructed from formalin-fixed, paraffin-embedded tumor blocks from 69 ccRCC tumors and 11 matched normal kidneys collected at the time of nephrectomy. Hematoxylin and eosin-stained slides were reviewed to identify a target area of ccRCC histology in each tissue block. TMAs were then constructed using 0.6-mm cores on the manual tissue microarrayer (Beecher Instruments). Tumor and normal samples were represented in triplicate. Sequential 4-μm slides were cut from each TMA.

Immunohistochemical (IHC) staining of H3K36me3, histone H3, and SETD2 was performed (Bond Autostainer, Leica Microsystems, Inc.) according to the manufacturer's protocol. Antigen retrieval for H3K36me3, SETD2, and histone H3 was performed for 30 min in citrate buffer (pH 6.0) (Bond #AR9961) and hydrated with Bond wash buffer (AR9590). Slides were incubated with H3K36me3 antibody (Abcam, ab9050, dilution 1:2000) or histone H3 (courtesy of the Strahl laboratory, dilution 1:5000) or SETD2 (Abcam, ab31358, 1:200) for 1 h at room temperature. Antibody detection was performed (Bond Polymer Refine Detection System, DS9800) followed by image acquisition (ScanScope CS, Aperio Technologies).

Quantification of H3K36me3, SETD2, and histone H3 was performed independently by two reviewers who were blinded to the tissue identity. The percentage of tumor cells with positive nuclei was determined by evaluating the entire core for each sample. The degree of H3K36me3 or SETD2 staining was averaged across triplicate samples and normalized to total H3 to correct for differences in cell number. Using the minimum value of normalized H3K36me3 in normal kidney as a cutoff, tumors were stratified as either “H3K36me3-normal” or “H3K36me3-deficient” for subsequent analyses. Five additional tumors (not represented on the tissue microarray) were similarly assessed by immunohistochemistry and classified as “H3K36me3-deficient” (three tumors) or “H3K36me3-normal” (two tumors).

Intron retention estimates by RNA-seq

Total RNA was isolated from tumors (miRNeasy, Qiagen) and validated to have a median RNA Integrity Numbers (RIN) of 8.6 (minimum 6.8) using a Bioanalyzer (Agilent). Ribosomal RNA was depleted (RiboMinus, Invitrogen) and RNA was fragmented (RNA Fragmentation Reagents, Ambion). cDNA was generated (SuperScript II, Invitrogen) by random priming followed by second strand synthesis (DNA polymerase I, Enzymatics) and purified (PCR purification kit, Qiagen). Libraries were prepared according to the manufacturer's specifications (Illumina). Sequencing was performed using 50-bp single-end reads (Illumina HiSeq 2000). Reads were aligned to the reference human genome (hg19) using TopHat (Trapnell et al. 2009), and gene expression was estimated by calculating RPKM, analyzing only exonic reads. Intron retention scores were calculated for each gene as follows:

$$2 \times \frac{\frac{\sum \text{intronic coverage}}{\sum \text{intronic length}}}{\frac{\sum \text{exonic coverage}}{\sum \text{exonic length}} + \frac{\sum \text{intronic coverage}}{\sum \text{intronic length}}}$$

Table 1. Quantitative RT-PCR primer sequences

Gene	Direction	Primer sequences (5' to 3')
<i>ABCF1</i>	Forward	CGCCAAGCCATGTTAGAAAATG
	Reverse	CGGCTACAATGTACAGGTCTG
<i>USH1C</i>	Forward1	ACCATCTCCAAACCTGTCATG
	Forward2	ATGATCAGGGAGTGAACC
	Reverse	CCATCCTCTTCAACATCTCCTG

Quantitative RT-PCR

Total RNA extracted from patient tumors (Qiagen miRNeasy) was either rRNA-depleted (RiboMinus, Invitrogen) or poly(A)-selected (Oligotex mRNA Mini Kit, Qiagen). RNA was reverse-transcribed by random priming (SuperScript II Reverse Transcriptase, Invitrogen), and cDNA was quantified by PCR and normalized to *ABCF1* (Maxima SYBR Green/ROX qPCR Master Mix, Thermo Fisher Scientific; 7900HT Fast Real-Time PCR System, Applied Biosystems) (see Table 1).

Differential splicing analysis

RNA-seq reads were aligned to the human reference genome using MapSplice (Wang et al. 2010). For each gene, a splicing graph was created as previously described (Singh et al. 2011). Each exon and splicing event was represented as an edge, and splice junctions as nodes. We computed a “splicing fraction” of each edge as the fraction of RNA-seq coverage in that edge divided by the total coverage of all edges sharing one node of that edge. Only edges with coverage exceeding 5 reads and genes with multiple isoforms (13,879 genes) were considered. The node exhibiting the largest difference between *SETD2* mutant and normal tumors was determined by comparing the median of each group. As a control, we created random groups of tumors of the same sizes. Splicing differences between *SETD2*-mutant and normal tumors were compared with that of the control group by a Kruskal–Wallis one-way analysis of variance test. The skipped exon ratio was computed as the ratio of coverage of the included exon, and the sum of coverages of the included exon and the skipping splice.

Data acquisition

TCGA data were accessed with authorization. Nephrectomy specimens were collected under institutional IRB-approved protocols.

Data access

Sequencing data and mutational analysis files have been submitted to EMBL-EBI ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>) under accession number E-MTAB-1936.

Acknowledgments

We acknowledge The Cancer Genome Atlas Consortium. We thank B. Strahl for advice and antibodies; W. Janzen, S. Pattenden, P. Dayton, and J. Streeter for assistance with DNA preparation; the UNC Tissue Procurement Facility for tissue acquisition; the UNC Translational Pathology Laboratory (TPL) for assistance with the tissue microarray fabrication and staining; and P. Mieczkowski and the High Throughput Sequencing Facility, J. Roach, and UNC Research Computing for sequencing data generation and initial processing. We gratefully acknowledge support from the National Cancer Institute (R01CA166447 to I.J.D. and R01CA121781 to W.K.R.), the National Human Genome Research Institute

(R01HG006272 to J.F.P.), the National Institute of General Medical Sciences (T32GM067553 to J.M.S. and T32GM008719 and T32GM08093 to K.E.H.), the V Foundation for Cancer Research, and the University of North Carolina University Cancer Research Fund (UCRF) Cancer Genetics Keystone Program. The TPL is supported, in part, by grants from the National Cancer Institute (3P30CA016086), National Institute of Environmental Health Sciences (3P30ES010126), Department of Defense (W81XWH-09-2-0042), and the UCRF.

Author contributions: J.M.S. and K.E.H. prepared tumor samples and nucleic acids and analyzed protein, transcriptomic, and genomic data and contributed equally to the preparation of the manuscript. J.S.P., J.F.P., and D.S. analyzed data for genomic and transcriptomic phenotypes. A.R.B., M.W., and T.S.F. performed data analysis and study design. T.H.H. and E.J. provided samples and data. P.-F.K. performed statistical analysis. J.D.L., W.K.R., and I.J.D. designed the study, analyzed the data, and wrote the manuscript. All authors have reviewed the manuscript and are knowledgeable of the results.

References

- Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. 2007. High-resolution profiling of histone methylations in the human genome. *Cell* **129**: 823–837.
- Batsche E, Yaniv M, Muchardt C. 2006. The human SWI/SNF subunit Brm is a regulator of alternative splicing. *Nat Struct Mol Biol* **13**: 22–29.
- Bratslavsky G, Sudarshan S, Neckers L, Linehan WM. 2007. Pseudohypoxic pathways in renal cell carcinoma. *Clin Cancer Res* **13**: 4667–4671.
- Brown MA, Sims RJ III, Gottlieb PD, Tucker PW. 2006. Identification and characterization of Smyd2: A split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. *Mol Cancer* **5**: 26.
- Carrozza MJ, Li B, Florens L, Suganuma T, Swanson SK, Lee KK, Shia WJ, Anderson S, Yates J, Washburn MP, et al. 2005. Histone H3 methylation by Set2 directs deacetylation of coding regions by Rpd3S to suppress spurious intragenic transcription. *Cell* **123**: 581–592.
- Carvalho S, Raposo AC, Martins FB, Grosso AR, Sridhara SC, Rino J, Carmo-Fonseca M, de Almeida SF. 2013. Histone methyltransferase SETD2 coordinates FACT recruitment with nucleosome dynamics during transcription. *Nucleic Acids Res* **41**: 2881–2893.
- Dalglish GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, et al. 2010. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. *Nature* **463**: 360–363.
- de Almeida SF, Grosso AR, Koch F, Fenouil R, Carvalho S, Andrade J, Levezinho H, Gut M, Eick D, Gut I, et al. 2011. Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36. *Nat Struct Mol Biol* **18**: 977–983.
- Dhayalan A, Rajavelu A, Rathert P, Tamas R, Jurkowska RZ, Ragozin S, Jeltsch A. 2010. The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and guides DNA methylation. *J Biol Chem* **285**: 26114–26120.
- Duns G, van den Berg E, van Duivenbode I, Osinga J, Hollema H, Hofstra RM, Kok K. 2010. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. *Cancer Res* **70**: 4287–4291.
- Edmunds JW, Mahadevan LC, Clayton AL. 2008. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. *EMBO J* **27**: 406–420.
- Feng J, Liu T, Qin B, Zhang Y, Liu XS. 2012. Identifying ChIP-seq enrichment using MACS. *Nat Protoc* **7**: 1728–1740.
- Fontebasso AM, Schwartzenuber J, Khuong-Quang DA, Liu XY, Sturm D, Korshunov A, Jones DT, Witt H, Kool M, Albrecht S, et al. 2013. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. *Acta Neuropathol* **125**: 659–669.
- Gaulton KJ, Nammo T, Pasquali L, Simon JM, Giresi PG, Fogarty MP, Panhuis TM, Mieczkowski P, Secchi A, Bosco D, et al. 2010. A map of open chromatin in human pancreatic islets. *Nat Genet* **42**: 255–259.
- Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med* **366**: 883–892.
- Giresi PG, Lieb JD. 2009. Isolation of active regulatory elements from eukaryotic chromatin using FAIRE (Formaldehyde Assisted Isolation of Regulatory Elements). *Methods* **48**: 233–239.

- Giresi PG, Kim J, McDaniel RM, Iyer VR, Lieb JD. 2007. FAIRE (Formaldehyde-Assisted Isolation of Regulatory Elements) isolates active regulatory elements from human chromatin. *Genome Res* **17**: 877–885.
- Goecks J, Nekrutenko A, Taylor J. 2010. Galaxy: A comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences. *Genome Biol* **11**: R86.
- Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, et al. 2008. HIF- α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. *Cancer Cell* **14**: 435–446.
- Gore ME, Larkin JM. 2011. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. *Br J Cancer* **104**: 399–406.
- Hakimi AA, Chen YB, Wren J, Gonen M, Abdel-Wahab O, Heguy A, Liu H, Takeda S, Tickoo SK, Reuter VE, et al. 2012. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. *Eur Urol* **63**: 848–854.
- Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P, Cheng JX, Murre C, Singh H, Glass CK. 2010. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol Cell* **38**: 576–589.
- Hogan GJ, Lee C-K, Lieb JD. 2006. Cell cycle-specified fluctuation of nucleosome occupancy at gene promoters. *PLoS Genet* **2**: e158.
- Howe KJ, Kane CM, Ares M Jr. 2003. Perturbation of transcription elongation influences the fidelity of internal exon inclusion in *Saccharomyces cerevisiae*. *RNA* **9**: 993–1006.
- Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, et al. 2012. State of the science: An update on renal cell carcinoma. *Mol Cancer Res* **10**: 859–880.
- Kadener S, Cramer P, Nogues G, Cazalla D, de la Mata M, Fededa JP, Werbajh SE, Srebrow A, Kornblihtt AR. 2001. Antagonistic effects of T-Ag and VP16 reveal a role for RNA Pol II elongation on alternative splicing. *EMBO J* **20**: 5759–5768.
- Kapur P, Pena-Llopis S, Christie A, Zhrebker L, Pavia-Jimenez A, Rathmell WK, Xie XJ, Brugarolas J. 2013. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: A retrospective analysis with independent validation. *Lancet Oncol* **14**: 159–167.
- Kim WY, Kaelin WG. 2004. Role of VHL gene mutation in human cancer. *J Clin Oncol* **22**: 4991–5004.
- Kolasinska-Zwierc P, Down T, Latorre I, Liu T, Liu XS, Ahringer J. 2009. Differential chromatin marking of introns and expressed exons by H3K36me3. *Nat Genet* **41**: 376–381.
- Kornblihtt AR. 2007. Coupling transcription and alternative splicing. *Adv Exp Med Biol* **623**: 175–189.
- Lassmann T, Hayashizaki Y, Daub CO. 2009. TagDust—a program to eliminate artifacts from next generation sequencing data. *Bioinformatics* **25**: 2839–2840.
- Li H, Durbin R. 2009. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* **25**: 1754–1760.
- Lickwar CR, Rao B, Shabalina AA, Nobel AB, Strahl BD, Lieb JD. 2009. The Set2/Rpd3S pathway suppresses cryptic transcription without regard to gene length or transcription frequency. *PLoS ONE* **4**: e4886.
- Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T. 2010. Regulation of alternative splicing by histone modifications. *Science* **327**: 996–1000.
- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytzky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. 2010. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res* **20**: 1297–1303.
- McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, Wenger AM, Bejerano G. 2010. GREAT improves functional interpretation of cis-regulatory regions. *Nat Biotechnol* **28**: 495–501.
- Munoz MJ, Perez Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, Boireau S, Glover-Cutter K, Ben-Dov C, Blaustein M, Lozano JJ, et al. 2009. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. *Cell* **137**: 708–720.
- Nagy PL, Cleary ML, Brown PO, Lieb JD. 2003. Genomewide demarcation of RNA polymerase II transcription units revealed by physical fractionation of chromatin. *Proc Natl Acad Sci* **100**: 6364–6369.
- Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, et al. 2008. Improved identification of von Hippel–Lindau gene alterations in clear cell renal tumors. *Clin Cancer Res* **14**: 4726–4734.
- Pena-Llopis S, Vega-Rubin-de-Celis S, Liao A, Leng N, Pavia-Jimenez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, et al. 2012. BAP1 loss defines a new class of renal cell carcinoma. *Nat Genet* **44**: 751–759.
- Pradeepa MM, Sutherland HG, Ule J, Grimes GR, Bickmore WA. 2012. Psp1/Ledgf p52 binds methylated histone H3K36 and splicing factors and contributes to the regulation of alternative splicing. *PLoS Genet* **8**: e1002717.
- Quinlan AR, Hall IM. 2010. BEDTools: A flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**: 841–842.
- Rashid NU, Giresi PG, Ibrahim JG, Sun W, Lieb JD. 2011. ZINBA integrates local covariates with DNA-seq data to identify broad and narrow regions of enrichment, even within amplified genomic regions. *Genome Biol* **12**: R67.
- Rayasam GV, Wendling O, Angrand PO, Mark M, Niederreither K, Song L, Lerouge T, Hager GL, Chambon P, Losson R. 2003. NSD1 is essential for early post-implantation development and has a catalytically active SET domain. *EMBO J* **22**: 3153–3163.
- Ryan RJ, Bernstein BE. 2012. Molecular biology. Genetic events that shape the cancer epigenome. *Science* **336**: 1513–1514.
- Saldanha AJ. 2004. Java Treeview—extensible visualization of microarray data. *Bioinformatics* **20**: 3246–3248.
- Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. 2011. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. *Blood* **117**: e207–e217.
- Schwartz S, Meshorer E, Ast G. 2009. Chromatin organization marks exon–intron structure. *Nat Struct Mol Biol* **16**: 990–995.
- Shin H, Liu T, Manrai AK, Liu XS. 2009. CEAS: cis-regulatory element annotation system. *Bioinformatics* **25**: 2605–2606.
- Simon JM, Giresi PG, Davis IJ, Lieb JD. 2012. Using formaldehyde-assisted isolation of regulatory elements (FAIRE) to isolate active regulatory DNA. *Nat Protoc* **7**: 256–267.
- Singh D, Orellana CF, Hu Y, Jones CD, Liu Y, Chiang DY, Liu J, Prins JF. 2011. FDM: A graph-based statistical method to detect differential transcription using RNA-seq data. *Bioinformatics* **27**: 2633–2640.
- Song L, Zhang Z, Grasfeder LL, Boyle AP, Giresi PG, Lee BK, Sheffield NC, Graf S, Huss M, Keefe D, et al. 2011. Open chromatin defined by DNaseI and FAIRE identifies regulatory elements that shape cell-type identity. *Genome Res* **21**: 1757–1767.
- Sun XJ, Wei J, Wu XY, Hu M, Wang L, Wang HH, Zhang QH, Chen SJ, Huang QH, Chen Z. 2005. Identification and characterization of a novel human histone H3 lysine 36-specific methyltransferase. *J Biol Chem* **280**: 35261–35271.
- Thurman RE, Rynes E, Humbert R, Vierstra J, Maurano MT, Haugen E, Sheffield NC, Stergachis AB, Wang H, Vernot B, et al. 2012. The accessible chromatin landscape of the human genome. *Nature* **489**: 75–82.
- Trapnell C, Pachter L, Salzberg SL. 2009. TopHat: Discovering splice junctions with RNA-Seq. *Bioinformatics* **25**: 1105–1111.
- Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, et al. 2011. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. *Nature* **469**: 539–542.
- Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, He X, Mieczkowski P, Grimm SA, Perou CM, et al. 2010. MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery. *Nucleic Acids Res* **38**: e178.
- Yoh SM, Lucas JS, Jones KA. 2008. The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation. *Genes Dev* **22**: 3422–3434.

Received March 29, 2013; accepted in revised form October 10, 2013.